Search Within


Applied Filters:
Showing 1-2 of 2 results for "603-32-7" within Papers
Daniel M Johnson et al.
Circulation. Arrhythmia and electrophysiology, 5(1), 201-209 (2011-11-15)
AZD1305 is an investigational antiarrhythmic agent for management of atrial fibrillation. It blocks various cardiac ion currents at different potencies and has atrial-predominant electrophysiological effects. We investigated the electrophysiological and proarrhythmic effects of AZD1305 versus dofetilide in dogs with chronic
B Le Grand et al.
Journal of cardiovascular pharmacology, 26(5), 803-809 (1995-11-01)
Action potential duration (APD) lengthening is believed to underlie the cardiac arrhythmogenicity of ketanserin, a serotonin (5-HT)2A/2C receptor antagonist. We wished to determine (a) whether this activity involves blockade of 5-HT2A/2C receptors and (b) the precise mechanism of ketanserin-induced APD
Page 1 of 1